Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Socinski

Showing results (31-40 of 279) with videos related to

Pageof 28
Sort By:
Lung Cancer (Amsterdam, Netherlands)|December 24, 2013
Temsirolimus therapy in a patient with lung adenocarcinoma harboring an FBXW7 mutationLiza C Villaruz, Mark A Socinski
Seminars in Radiation Oncology|November 24, 2004
Management of unresectable stage III non-small cell lung cancer: the role of combined chemoradiationShannon K Penland, Mark A Socinski
Cancer Investigation|October 10, 2003
96-hour paclitaxel infusions: at least 93 hours too longBert H O'Neil, Mark A Socinski
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 4, 2010
Maintenance therapy in advanced non-small cell lung cancer: current status and future implicationsThomas E Stinchcombe, Mark A Socinski
Seminars in Thoracic and Cardiovascular Surgery|March 27, 2012
Personalized therapy for non-small cell lung cancer: which drug for which patient?Liza C Villaruz, Mark A Socinski
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 21, 2007
Duration of first-line chemotherapy in advanced non small-cell lung cancer: less is more in the era of effective subsequent therapiesMark A Socinski, Thomas E Stinchcombe
Seminars in Oncology|July 15, 2005
Does more aggressive therapy improve outcomes in the treatment of unresectable stage III non-small cell lung cancer?Julian G Rosenman, Mark A Socinski
Seminars in Oncology|July 15, 2005
Chemotherapeutic issues in the management of unresectable stage III non-small cell lung cancerMark A Socinski, Julian G Rosenman
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2013
The clinical viewpoint: definitions, limitations of RECIST, practical considerations of measurementLiza C Villaruz, Mark A Socinski
Current Oncology Reports|May 8, 2015
The role of anti-angiogenesis in non-small-cell lung cancer: an updateLiza C Villaruz, Mark A Socinski
Pageof 28

Showing results (31-40 of 279) with videos related to

Sort By:
Pageof 28
Lung Cancer (Amsterdam, Netherlands)|December 24, 2013
Temsirolimus therapy in a patient with lung adenocarcinoma harboring an FBXW7 mutationLiza C Villaruz, Mark A Socinski
Seminars in Radiation Oncology|November 24, 2004
Management of unresectable stage III non-small cell lung cancer: the role of combined chemoradiationShannon K Penland, Mark A Socinski
Cancer Investigation|October 10, 2003
96-hour paclitaxel infusions: at least 93 hours too longBert H O'Neil, Mark A Socinski
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 4, 2010
Maintenance therapy in advanced non-small cell lung cancer: current status and future implicationsThomas E Stinchcombe, Mark A Socinski
Seminars in Thoracic and Cardiovascular Surgery|March 27, 2012
Personalized therapy for non-small cell lung cancer: which drug for which patient?Liza C Villaruz, Mark A Socinski
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 21, 2007
Duration of first-line chemotherapy in advanced non small-cell lung cancer: less is more in the era of effective subsequent therapiesMark A Socinski, Thomas E Stinchcombe
Seminars in Oncology|July 15, 2005
Does more aggressive therapy improve outcomes in the treatment of unresectable stage III non-small cell lung cancer?Julian G Rosenman, Mark A Socinski
Seminars in Oncology|July 15, 2005
Chemotherapeutic issues in the management of unresectable stage III non-small cell lung cancerMark A Socinski, Julian G Rosenman
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2013
The clinical viewpoint: definitions, limitations of RECIST, practical considerations of measurementLiza C Villaruz, Mark A Socinski
Current Oncology Reports|May 8, 2015
The role of anti-angiogenesis in non-small-cell lung cancer: an updateLiza C Villaruz, Mark A Socinski
Pageof 28